Clinical Trial Update: Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ABBV-637 or ABBV-155 in combination with ERAS-801 for glioblastoma and gliosarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• ABBV-155
• ABBV-637
• ERAS-801

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Glioblastoma, Gliosarcoma | Phase 1 | Status: RECRUITING